¼¼°èÀÇ ¹«¹Ù´Ã ¾à¹° ÁÖÀÔ ½Ã½ºÅÛ ½ÃÀå
Needle-Free Drug Injection Systems
»óǰÄÚµå : 1514164
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 278 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,009,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,027,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¹«¹Ù´Ã ¾à¹° ÁÖÀÔ ½Ã½ºÅÛ ½ÃÀåÀº 2030³â±îÁö 299¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2023³â¿¡ 159¾ï ´Þ·¯·Î Æò°¡µÈ ¼¼°èÀÇ ¹«¹Ù´Ã ¾à¹° ÁÖÀÔ ½Ã½ºÅÛ ½ÃÀåÀº 2030³â¿¡´Â 299¾ï ´Þ·¯¿¡ À̸¦ Àü¸ÁÀ̸ç, ºÐ¼® ±â°£ 2023³âºÎÅÍ 2030³â±îÁö CAGRÀº 9.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Á¦Æ® ÀÎÁ§ÅÍ ±â¼úÀº CAGR 9.5%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, ºÐ¼® ±â°£ Á¾·á±îÁö 95¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½Å±Ô ´Ïµé ÇÁ¸® ±â¼ú ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 8.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 42¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 12.5%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¹«¹Ù´Ã ¾à¹° ÁÖÀÔ ½Ã½ºÅÛ ½ÃÀåÀº 2023³â 42¾ï ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 67¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ 2023³âºÎÅÍ 2030³â±îÁö CAGRÀº 12.5%·Î Àü¸ÁµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 6.1%¿Í 7.8%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 7.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¹«¹Ù´Ã ¾à¹° ÁÖÀÔ ½Ã½ºÅÛ-ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ

¹«¹Ù´Ã ¾à¹° ÁÖÀÔ ½Ã½ºÅÛÀº µ¿¹° °Ç°­ °ü¸®, ƯÈ÷ ¾çµ· »ê¾÷¿¡¼­ Áß¿äÇÑ Çõ½ÅÀ̸ç, ±âÁ¸ÀÇ ÁÖ»ç ¹Ù´ÃÀ» ´ëüÇÏ´Â È¿°úÀûÀÎ ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ±â¼úÀº µ¿¹°ÀÇ °Ç°­ »óŸ¦ Çâ»ó½Ã۰í, °æ¿µ ºñ¿ëÀ» ÁÙÀ̰í, À°·ù »ý»êÀÇ Àü¹ÝÀûÀÎ ¾ÈÀü¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. ¹«¹Ù´Ã ½Ã½ºÅÛÀº °í¾Ð Á¦Æ® ±â·ù¸¦ ¹ß»ý½ÃŰ°í µ¿¹° Á¶Á÷¿¡ ħÅõ½ÃÄÑ ¾à¹°À̳ª ¹é½ÅÀ» Åõ¿©Çϰí, Çdz», ÇÇÇÏ, ±ÙÀ° ³»¿¡ Á÷Á¢ Åõ¿©ÇÕ´Ï´Ù. ÀÌ ¹æ¹ýÀº Á¤È®ÇÑ º¹¿ë·®°ú º¹¿ë ±íÀ̸¦ º¸ÀåÇÒ»Ó¸¸ ¾Æ´Ï¶ó ´Ù¾çÇÑ µ¿¹°ÀÇ Å©±â¿¡ ÀûÀÀÇϱ⠶§¹®¿¡ »õ³¢ µÅÁö¿¡¼­ ÀÚ¶õ ¸äµÅÁö¿Í µÅÁö±îÁö ÀûÇÕÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº °­·ÂÇÑ ¸é¿ª ¹ÝÀÀÀ» À¯¹ßÇÏ´Â µ¥ È¿°úÀûÀ̸ç Á¾Á¾ ±âÁ¸ ¹æ¹ýº¸´Ù ¿ì¼öÇϱ⠶§¹®¿¡ Ãà»ê¿¡¼­ Ç¥ÁØ ¹é½Å Á¢Á¾ ÇÁ·ÎÅäÄݰú Ä¡·á¹ý¿¡ Çõ¸íÀ» ÀÏÀ¸Å³ °¡´É¼ºÀÌ °­Á¶µË´Ï´Ù.

¹«¹Ù´Ã ÁÖ»ç ±â¼úÀÇ µµÀÔÀº ±âÁ¸ÀÇ ÁÖ»ç±â¿Í °ü·ÃµÈ ¸î °¡Áö ½É°¢ÇÑ ¾ÈÀü ¹®Á¦¸¦ ÇØ°áÇÕ´Ï´Ù. ÁÖ»ç ¹Ù´ÃÀÌ ºÎ·¯Áö´Â À§ÇèÀ» Á¦°ÅÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ½ÄǰÀÇ ¾ÈÀü¼ºÀ» ³ôÀÌ°í ¼ÒºñÀÚÀÇ °Ç°­À» º¸È£ÇÕ´Ï´Ù. ¶ÇÇÑ ÁÖ»ç ¹Ù´ÃÀ» »ç¿ëÇÏÁö ¾Ê±â ¶§¹®¿¡ µÅÁö ¹ø½Ä ¹× È£Èí±â ÁõÈıº(PRRS)°ú °°Àº Áúº´ÀÇ ¸¸¿¬À¸·Î À̾îÁú ¼ö ÀÖ´Â ÁÖ»ç ¹Ù´Ã·Î ÀÎÇÑ ÀϹÝÀûÀÎ ¹®Á¦ÀÎ °¡Ãà °£ÀÇ 2 Â÷ ¿À¿° À§ÇèÀÌ °¨¼ÒµË´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ½Ã½ºÅÛÀÇ ¼³°èÀû Ư¡Àº ¿ì¹ßÀûÀÎ ÀÚ°¡ÁÖ»ç¿Í ³óÀå³ëµ¿ÀÚÀÇ ¹Ýº¹¿îµ¿¿¡ ÀÇÇÑ ºÎ»óÀ» ÃÖ¼ÒÈ­ÇÔÀ¸·Î½á »ç¿ëÀÚÀÇ ¾ÈÀüÀ» ¿ì¼±½ÃÇÏ°í º¸´Ù ¾ÈÀüÇϰí ÀÎü°øÇÐÀû ÀÛ¾÷ ȯ°æ¿¡ ±â¿©ÇÕ´Ï´Ù. ±×·¯³ª ¹«¹Ù´Ã ÁÖ»ç±â·ÎÀÇ ÀüȯÀº Ãʱâ ÅõÀÚ¿Í Áö¼ÓÀûÀÎ À¯Áö º¸¼ö¿Í °°Àº Á÷Á¢ ¹× °£Á¢ ºñ¿ëÀ» ½ÅÁßÇÏ°Ô °í·ÁÇØ¾ß ÇÕ´Ï´Ù.

¹«¹Ù´Ã ¾à¹° ÁÖÀÔ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀº ¾à¹°Àü´Þ ¸ÞÄ¿´ÏÁò°ú ÀåºñÀÇ ÀÎü °øÇÐÀ» Çâ»ó½ÃŰ´Â Áö¼ÓÀûÀÎ ±â¼ú Çõ½Å°ú °°Àº ¿©·¯ ¿äÀο¡ ÀÇÇØ ¾ß±âµË´Ï´Ù. ÀÌ·¯ÇÑ Áøº¸´Â ½Ã½ºÅÛÀ» º¸´Ù È¿À²ÀûÀÌ°í »ç¿ëÇϱ⠽±°í ±¤¹üÀ§ÇÑ Ã¤¿ëÀ» ÃËÁøÇÕ´Ï´Ù. ¹Ù´Ã ÁÖ»ç ¼Õ»ó ¹× °ü·Ã ¹ýÀû Ã¥ÀÓÀ» ÁÙÀ̱â À§ÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ¹× ¾ÈÀü ±âÁصµ ¹Ù´ÃÀ» »ç¿ëÇÏÁö ¾Ê´Â ½Ã½ºÅÛÀ¸·ÎÀÇ À̵¿À» ÃËÁøÇÕ´Ï´Ù. ÇコÄɾî Á¾»çÀÚÀÇ ÁöÁö¿Í ħ½ÀÀÌ ÀûÀº Ä¡·á¹ýÀ» ¿ä±¸Çϴ ȯÀÚÀÇ ¿ä±¸´Â ƯÈ÷ ÁÖ»ç ¹Ù´ÃÀ» ½È¾îÇÏ´Â »ç¶÷µé »çÀÌ¿¡¼­ ÀÌ·¯ÇÑ µ¿Çâ¿¡ ´õ¿í ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ ½Ã½ºÅÛÀ» µðÁöÅÐ ÀÇ·á ±â·Ï°ú ÅëÇÕÇϸé ȯÀÚ µ¥ÀÌÅÍ °ü¸®°¡ ½¬¿öÁö°í ¿öÅ©Ç÷οì È¿À²¼ºÀÌ Çâ»óµË´Ï´Ù. ÁÖ»ç ¹Ù´ÃÀ» »ç¿ëÇÏÁö ¾Ê´Â ½Ã½ºÅÛÀº ƯÈ÷ Áý´Ü ¿¹¹æ Á¢Á¾ ÇÁ·Î±×·¥ÀÇ ºñ¿ë È¿À²ÀûÀÌ°í ºü¸£°í ½¬¿î ¹é½Å Åõ¿©¸¦ ½ÇÇöÇÕ´Ï´Ù. ¸¶Áö¸·À¸·Î, ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ÀÏȸ¿ë ÁÖ»ç ¹Ù´Ã°ú °ü·ÃµÈ ÀÇ·á Æó±â¹°À» ÁÙÀÓÀ¸·Î½á ȯ°æ Áö¼Ó°¡´É¼º ¸ñÇ¥¿¡ ºÎÇÕÇÏ¸ç ±â¼ú È¿À²¼º, ȯÀÚ ÆíÀǼº, ȯ°æ¿¡ ´ëÇÑ ¹è·Á°¡ Á¡Á¡ ¿ì¼±½Ã µÇ°í ÀÖ´Â Çö´ëÀÇ ÇコÄɾî ȯ°æ¿¡ À־, ±× ¸Å·ÂÀ» µÎµå·¯Áö°Ô Çϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 52°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Needle-Free Drug Injection Systems Market to Reach US$29.9 Billion by 2030

The global market for Needle-Free Drug Injection Systems estimated at US$15.9 Billion in the year 2023, is expected to reach US$29.9 Billion by 2030, growing at a CAGR of 9.4% over the analysis period 2023-2030. Jet Injectors Technology, one of the segments analyzed in the report, is expected to record a 9.5% CAGR and reach US$9.5 Billion by the end of the analysis period. Growth in the Novel Needle-Free Technology segment is estimated at 8.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.2 Billion While China is Forecast to Grow at 12.5% CAGR

The Needle-Free Drug Injection Systems market in the U.S. is estimated at US$4.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$6.7 Billion by the year 2030 trailing a CAGR of 12.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.1% and 7.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.

Needle-Free Drug Injection Systems - Key Trends and Drivers

Needle-free drug injection systems represent a significant innovation in the realm of animal healthcare, particularly within the swine industry, offering a viable alternative to traditional needle-based injections. This technology enhances animal health outcomes, reduces operational costs, and improves the overall safety of meat production. Needle-free systems administer medications or vaccines by creating a high-pressure jet stream capable of penetrating animal tissue, delivering substances directly into intradermal, subcutaneous, or intramuscular layers. This method not only ensures precise dosage and depth of administration but also adapts to various animal sizes, making it suitable from piglets to full-grown boars and sows. The effectiveness of these systems in eliciting robust immune responses, often superior to traditional methods, underscores their potential to revolutionize standard vaccination protocols and therapeutic treatments in animal husbandry.

The implementation of needle-free injection technology addresses several significant safety concerns associated with conventional syringes. By eliminating the risk of needle breaks, these systems enhance food safety and protect consumer health, crucial for maintaining the integrity and marketability of meat products, especially in export markets. Furthermore, needle-free injections reduce the risk of cross-contamination between animals, a common issue with needle injections that can lead to the spread of diseases such as porcine reproductive and respiratory syndrome (PRRS). The design features of these systems also prioritize user safety by minimizing accidental self-injection and repetitive motion injuries among farm workers, contributing to a safer and more ergonomic work environment. However, the transition to needle-free technology requires careful consideration of the direct and indirect costs, including the initial investment and ongoing maintenance of the devices, which may be offset by long-term benefits such as reduced disease transmission and medication costs in larger operations.

The growth of the needle-free drug injection system market is driven by multiple factors, including continuous technological innovations that enhance drug delivery mechanisms and device ergonomics. These advancements make the systems more efficient and user-friendly, fostering broader adoption. Stricter regulatory and safety standards aimed at reducing needlestick injuries and related liabilities also promote the shift towards needle-free systems. Healthcare worker advocacy and patient demand for less invasive treatment options further influence this trend, especially among individuals with needle aversions. Additionally, the integration of these systems with digital health records facilitates better patient data management, enhancing workflow efficiency. Needle-free systems are particularly cost-effective for mass immunization programs, providing quick and easy vaccine administration. Lastly, these systems align with environmental sustainability goals by reducing medical waste associated with disposable needles, highlighting their appeal in modern healthcare settings where technological efficiency, patient comfort, and environmental considerations are increasingly prioritized.

Select Competitors (Total 52 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â